HEALTH OF WOMAN. 2019.7(143): 16–21; doi 10.15574/HW.2019.143.16

V.A. Zabolotnov, V.I. Shatilo, O.A. Khvatova, Y.P. Szegedina
Zhytomyr Medical Institute

In 30–50% of women with PCOS, functional hyperprolactinemia is detected. In assisting women with PCOS and functional hyperherolactinemia, an integrated approach is required, both in diagnosis and treatment. The use of Mastodinon®, Cyclodinon® preparations containing the exact dosing amount of Vitex agnus-castus in women with PCOS and functional hyperheprolactinemia positively affects the hypothalamic-pituitary-ovarian axis and corrects the main clinical symptoms, prevents the occurrence of hyperplastic processes in the genitals, and increases fertility.
Key words: polycystic ovary syndrome, functional hyperprolactinemia, Vitex agnus-castus, Mastodynon®, Cyclodynon®.

REFERENCES

1. Azziz R, Adashi EY. 2016 Feb. Stein and Leventhal: 80 years on. Am J Obstet Gynecol.  214(2):247. https://doi.org/10.1016/j.ajog.2015.12.013; PMid:26704896

2. International evidence-based guideline for the assessment and management of polycystic ovary syndrome: 196. 2018.

3. John E. 2008. Nestler Metformin for the Treatment of the Polycystic Ovary Syndrome. N Engl J Med 358:47-54. https://doi.org/10.1056/NEJMct0707092; PMid:18172174

4. Apter D, Vihko R. 1983. Early menarche, a risk factor for breast cancer, indicates early onset of ovulatory cycles. Journal of Clinical Endocrinology & Metabolism 57(1): 82-6. https://doi.org/10.1210/jcem-57-1-82; PMid:6222061

5. Van Hooff MH et al. 2004. Predictive value of menstrual cycle pattern, body mass index, hormone levels and polycystic ovaries at age 15 years for oligo-amenorrhoea at age 18 years. Hum Reprod 19(2): 383-92. https://doi.org/10.1093/humrep/deh079; PMid:14747186

6. International evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction 33;9:1602–1618, 2018.

7. Bozdag G et al. 2016. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 31(12): 2841-2855. https://doi.org/10.1093/humrep/dew218; PMid:27664216

8. Witchel SF et al. 2015. The Diagnosis of Polycystic Ovary Syndrome during Adolescence. Horm Res Paediatr. https://doi.org/10.1159/000375530; PMid:25833060

9. Vermeulen AL Verdonck, Kaufman J. 1999. A critical evaluation of simple methods for the estimation of free testosterone in serum. Journal of Clinical Endocrinology & Metabolism 84(10): 3666-3672. https://doi.org/10.1210/jcem.84.10.6079; PMid:10523012

10. Rosner W and Vesper H. 2010. Toward excellence in testosterone testing: A consensus statement. Journal of Clinical Endocrinology & Metabolism 95(10): 4542-4548. https://doi.org/10.1210/jc.2010-1314; PMid:20926540

11. Taieb J, Mathian B and Millot F et al. 2003. Testosterone measured by 10 immunoassays and by radio-isotopedilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clinical Chemistry 49: 1381-1395. https://doi.org/10.1373/49.8.1381; PMid:12881456

12. Saini S et al. 2016. Gaps in knowledge in diagnosis and management of polycystic ovary syndrome. Fertility and Sterility 106(3): e100. https://doi.org/10.1016/j.fertnstert.2016.07.289

13. Bili AE et al. 2014. The combination of ovarian volume and outline has better diagnostic accuracy than prostatespecific antigen (PSA) concentrations in women with polycystic ovarian syndrome (PCOS). European Journal of Obstetrics & Gynecology and Reproductive Biology 179: 32-35. https://doi.org/10.1016/j.ejogrb.2014.05.006; PMid:24965976

14. Freda PU, Beckers AM, Katznelson L, Molitch ME and oth. 2011, Apr. Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab.  96(4):894-904. doi: 10.1210/jc.2010-1048. https://doi.org/10.1210/jc.2010-1048; PMid:21474686 PMCid:PMC5393422

15. Lavin N. 1994. Manual of Endocrinology and Metabolism: 224–227.

16. Escobar-Morreale H et al. 2001. Receiver operating characteristic analysis of the performance of basal serum hormone profiles for the diagnosis of polycystic ovary syndrome in epidemiological studies. European Journal of Endocrinology 145(5): 619-624. https://doi.org/10.1530/eje.0.1450619; PMid:11720881

17. Deeks A, Gibson-Helm M, Teede H. 2011. Is having polycystic ovary syndrome (PCOS) a predictor of poor psychological function including depression and anxiety. Human Reproduction. Advance access published 2011, March 23. https://doi.org/10.1093/humrep/der071; PMid:21436137

18. Koskinen P et al. 1996. Optimal use of hormone determinations in the biochemical diagnosis of the polycystic ovary syndrome. Fertility & Sterility 65(3): 517-22. https://doi.org/10.1016/S0015-0282(16)58146-1

19. Dedov II, Melnichenko GA. 2016. Klinicheskie rekomendatsii: diagnostika i lechebno-profilakticheskie meropriyatiya pri vrozhdennoy disfunktsii koryi nadpochechnikov u patsientov vo vzroslom vozraste.

20. Zabolotnov VA, Shatilo VI, Rybalka AN, Kupriyanenko AV. 2017. Ot nedostatochnosti lyuteinovoy fazyi k gipotalamo-gipofizarno-yaichnikovoy disfunktsii. Zdorove zhenschiny 8: 35–39.

21. Zabolotnov VA, Shatilo VI, Ryibalka AN, Kupriyanenko AV. 2018, Traven. Ot nedostatochnosti lyuteinovoy fazy k gipotalamo-gipofizarno-yaichnikovoy disfunktsii. Reproduktivna endokrinologiya 3 (41): 73–76.